Publication date: Aug 11, 2019
Most recently the FDA awarded MMJ International Holdings ″Orphan Drug Designation″ for its THC and CBD proprietary drug formulation which will be used for the treatment of Huntington’s Disease.
The drugs, MMJ-001 and MMJ-002 are two of MMJ’s lead drugs that the company is confident will bring much needed relief to patients suffering from the debilitating effects of Multiple Sclerosis and Huntington’s Disease.
“We firmly believe that our MMJ natural whole plant derived molecules with a unique combination of pharmacological properties will be FDA approved as a safe and effective prescription drug that can be of great benefit in treating patients with MS and HD diseases,” said Duane Boise, CEO of MMJ International Holdings.
Tim Moynahan the company chairman stated that “Patients in the MMJ International holdings clinical trials will receive gelatin capsules containing THC and CBD daily.
- CNBC Features MMJ International Holdings on FDA, DEA Approved Marijuana Studies
- MMJ BioPharma Cultivation and Native American Tribe Moving Forward With Marijuana DEA Application
- Cannabinoid Derivatives Show Therapeutic Potential in Mouse Model, But EHP-102 Still Superior